HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: ERC-08-0190v1 16/1/281    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Guillemot, J. Articles by Lefebvre, H. Search for Related Content PubMed PubMed Citation Articles by Guillemot, J. Articles by Lefebvre, H.

¹ INSERM U413, EA4310, DC2N, IFRMP 23, University of Rouen, Mont Saint Aignan, France² INSERM U644, Department of Pharmacology, Institute of Biomedical Research, Rouen University Hospital, Rouen, France³ Laboratory of Oncologic Genetics, Centre Henri Becquerel, Rouen, France⁴ Department of Endocrinology, Institute of Biomedical Research, Rouen University Hospital, Rouen, France⁵ Hypertension Unit, Paris Descartes University, AP-HP, Hôpital Européen Georges Pompidou, Paris, France⁶ INSERM U567, Department of Endocrinology, Cochin Institute, CNRS UMR8104, Cochin Hospital, Paris Descartes University, AP-HP, Paris, France

(Correspondence should be addressed to H Lefebvre, INSERM U413, IFRMP 23, Department of Endocrinology, Hospital of Boisguillaume, CHU of Rouen, 76031 Rouen Cedex, France; Email: herve.lefebvre{at}chu-rouen.fr)

The gastroprokinetic agent metoclopramide is known to stimulate catecholamine secretion from pheochromocytomas. The aim of the study was to investigate the mechanism of action of metoclopramide and expression of serotonin type 4 (5-HT₄) receptors in pheochromocytoma tissues. Tissue explants, obtained from 18 pheochromocytomas including the tumor removed from a 46-year-old female patient who experienced life-threatening hypertension crisis after metoclopramide administration and 17 additional pheochromocytomas (9 benign and 8 malignant) were studied. Cultured pheochromocytoma cells derived from the patient who previously received metoclopramide were incubated with metoclopramide and various 5-HT₄ receptor ligands. In addition, total mRNAs were extracted from all the 18 tumors. Catecholamine- and granin-derived peptide concentrations were measured in pheochromocytoma cell incubation medium by HPLC and radioimmunological assays. In addition, expression of 5-HT₄ receptor mRNAs in the 18 pheochromocytomas was investigated by the use of reverse transcriptase-PCR. Results: Metoclopramide and the 5-HT₄ receptor agonist cisapride were found to activate catecholamine- and granin-derived peptide secretions by cultured tumor cells. Metoclopramide- and cisapride-evoked catecholamine- and granin-derived peptide productions were inhibited by the 5-HT₄ receptor antagonist GR 113808. 5-HT₄ receptor mRNAs were detected in the patient's tumor and the series of 17 additional pheochromocytomas. This study shows that pheochromocytomas express functional 5-HT₄ receptors that are responsible for the stimulatory action of metoclopramide on catecholamine- and granin-derived peptide secretion. All 5-HT₄ receptor agonists must therefore be contraindicated in patients with proven or suspected pheochromocytoma.